Cost-effectiveness of duloxetine: The stress urinary incontinence treatment (SUIT) study

Value in Health

Volumn 13, Issue 5, 2010, Pages 565-572

  Mihaylova, Borislava ^a   Pitman, Richard ^b   Tincello, Douglas ^c   Van Der Vaart, Huub ^d   Tunn, Ralf ^e   Timlin, Louise ^f   Quail, Deborah ^f   Johns, Adam ^f   Sculpher, Mark ^b,g  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ICON PLC   (United Kingdom)

^c UNIVERSITY OF LEICESTER   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^e St Hedwig Hospitals   (Germany)

^f ELI LILLY AND COMPANY   (United States)

^g UNIVERSITY OF YORK   (United Kingdom)

Author keywords

cost effectiveness analysis; EQ 5D; observational study; outcomes research; women's health

Indexed keywords

DULOXETINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY ADJUSTED LIFE YEAR; STRESS INCONTINENCE; UNITED KINGDOM;

EID: 77955408795     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1111/j.1524-4733.2010.00729.x     Document Type: Article

References (29)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology 2003 61 : 37 49.
2. Hunskaar S, Lose G, Sykes D, Voss S. The prevalence of urinary incontinence in women in four European countries. BJU Int 2004 93 : 324 330.
3. Hunskaar S, Burgio K, Diokno A, et al. Epidemiology and natural history of urinary incontinence in women. Urology 2003 62 (Suppl. 1 S16 23. (Pubitemid 41116578)
4. Vandoninck V, Bemelmans BL, Mazzetta C, et al. The prevalence of urinary incontinence in community-dwelling married women: a matter of definition. BJU Int 2004 94 : 1291 1295.
5. Hannestad YS, Rortveit G, Sandvik H, Hunskaar S, Norwegian EsEoIitCoN-T. A community-based epidemiological survey of female urinary incontinence: the Norwegian EPINCONT study. Epidemiology of Incontinence in the County of Nord-Trondelag. J Clin Epidemiol 2000 53 : 1150 1157.
6. Thom D. Variation in estimates of urinary incontinence prevalence in the community: effects of differences in definition, population characteristics, and study type. J Am Geriatr Soc 1998 46 : 473 480.
7. National Collaborating Centre for Women's and Children's Health. Urinary Incontinence - The Management of Urinary Incontinence in Women. London : Royal College of Obstetricians and Gynaecologists (RCOG), 2006.
8. Sykes D, Castro R, Pons ME, et al. Characteristics of female outpatients with urinary incontinence participating in a 6-month observational study in 14 European countries. Maturitas 2005 52 (Suppl. 2 13 23.
9. Papanicolaou S, Pons ME, Hampel C, et al. Medical resource utilisation and cost of care for women seeking treatment for urinary incontinence in an outpatient setting. Examples from three countries participating in the PURE study. Maturitas 2005 52 (Suppl. 2 35 47.
10. Viktrup L, Bump RC. Pharmacological agents used for the treatment of stress urinary incontinence in women. Curr Med Res Opin 2003 19 : 485 490.
11. Mariappan P, Alhasso A, Ballantyne Z, et al. Duloxetine, a serotonin and noradrenaline reuptake inhibitor (SNRI) for the treatment of stress urinary incontinence: a systematic review. Eur Urol 2007 51 : 67 74.
12. Das Gupta R, Caiado M, Bamber L. An evaluation of the cost-effectiveness of duloxetine as a treatment for women with moderate-to-severe stress urinary incontinence. J Med Econ 2006 9 : 27 44.
13. Brunenberg DEM, Joore MA, Veraart CPWM, et al. Economic evaluation of duloxetine for the treatment of women with stress urinary incontinence: a Markov model comparing pharmacotherapy with pelvic floor muscle training. Clin Ther 2006 28 : 604 618.
14. Van der Vaart H, Falconer C, Quail D, et al. Patient reported outcomes tools in an observational study of female stress urinary incontinence. Neurourol Urodyn 2010 29 : 348 353.
15. Royston P. Multiple imputation of missing values. Stata J 2004 4 : 227 241.
16. Kind P. The EuroQoL instrument: an index of health-related quality of life. In : Spilker B, ed. Quality of Life and Pharmacoeconomics in Clinical Trials (2nd ed.). Philadelphia, PA : Lippincott-Raven, 1996.
17. Dolan P, Gudex C, Kind P, Williams A. A Social Tariff for EuroQol: Results from a UK General Population Survey. Centre for Health Economics Discussion Paper 138. York : Centre for Health Economics, University of York: CHE, 1995.
18. Matthews JNS, Altman D, Campbell MJ. Analysis of serial measurements in medical research. BMJ 1990 300 : 230 235. (Pubitemid 20045528)
19. Unit Costs of Health and Social Care 2007. Canterbury, Kent: Personal Social Services Research Unit, University of Kent http://www.pssru.ac.uk/uc/ uc2007contents.htm 2007; accessed on March 3, 2008.
20. Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost-effectiveness data. Health Econ 2004 13 : 461 475.
21. Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc 1984 79 : 516 524.
22. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983 70 : 41 55.
23. Becker SO, Ichino A. Estimation of average treatment effects based on propensity scores. Stata J 2002 2 : 358 377.
24. National Institute for Health and Clinical Excellence (NICE). Guide to the Methods of Technology Appraisal. London : NICE, 2008.
25. Tincello D, Sculpher M, Tunn R, et al. Patient characteristics impacting health state index scores, measured by the EQ-5D of females with stress urinary incontinence symptoms. Value Health 2010 13 : 112 118.
26. Sculpher M, Claxton K, Akehurst R. It's just evaluation for decision making: recent developments in, and challenges for, cost-effectiveness research. In : Smith PC, Ginnelly L, Sculpher M, eds. Health Policy and Economics. Opportunities and Challenges. Maidenhead : Open University Press, 2005.
27. Drummond MF. Experimental versus observational data in the economic evaluation of pharmaceuticals. Med Decis Making 1998 18 (Suppl. S12 18.
28. Hadley J, Polsky D, Mandelblatt JS, et al. An exploratory instrumental variable analysis of the outcomes of localized breast cancer treatments in a medicare population. Health Econ 2003 12 : 171 186.
29. McClellan M, McNeil BJ, Newhouse JP. Does more intensive treatment of acute myocardial infarction in the elderly reduce mortality? Analysis using instrumental variables See comment JAMA 1994 272 : 859 866.